September 29, 2026 · High impact · Updated Sep 29, 2026
Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready, once-weekly oral GLP-1/GIP dual receptor agonist. The deal is valued at up to $2.6 billion, including a $300 million upfront payment and potential sales royalties, indicating a significant strategic move in the diabetes and obesity drug market.
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.
This week
2 of 24 shown
See the full board →Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
